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PPARc ligands attenuate mesangial contractile dysfunction in
high glucose.
Background. To elucidate the regulation of peroxisome
proliferator–activated receptor c (PPARc) and its roles in
mesangial cells, we examined the expression of PPARc1 and
effects of its ligands on cell phenotypes and angiotensin II–
induced contractile response in cultured rat mesangial cells un-
der a high (20 mmol/L) glucose condition.
Methods. The effects of tumor necrosis factor a (TNFa), pro-
tein kinase C (PKC) activation, antisense DNA for PPARc1,
PPARc ligands and PD98059 were examined in mesangial cells
cultured in either 5 mmol/L or 20 mmol/L glucose. The expres-
sions of PPARc1 protein and a-smooth muscle actin (aSMA)
as a marker of phenotype of cells were determined by Western
blot. The expression of PPARc1 mRNA was determined by a
reverse transcription-polymerase chain reaction method. The
reduction of cell surface area in response to angiotensin II was
measured by microscope to determine cellular contraction.
Results. PKC activation, TNFa, and 20 mmol/L glucose de-
creased PPARc1 at both protein and mRNA levels, which was
inhibited by PD98059, a specific inhibitor of mitogen-activated
protein kinase (MAPK). Decreases of PPARc1 protein and con-
tractile response and an increase of aSMA occurred simultane-
ously in the cells treated with 20 mmol/L glucose after 5 days,
which were attenuated to the normal levels by PPARc ligands.
The antisense DNA also induced the decrease of PPARc1 pro-
tein, contractile dysfunction, and increase of aSMA.
Conclusion. MAPK suppresses PPARc1 at the transcrip-
tional level, and the reduction of PPARc1 in cultured rat mesan-
gial cells under the high glucose condition induces phenotypic
change and loss of contractile function. PPARc ligands recover
both reductions of PPARc 1 protein and contractile response.
Peroxisome proliferator–activated receptor c
(PPARc) is a nuclear receptor and plays an important
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role in regulation of cell differentiation at transcriptional
levels [1–3]. Fibroblasts are reported to differentiate
to adipocytes by the activation of PPARc [1]. We also
reported the expression of PPARc1 in rat mesangial
cells and the function of PPARc1 to regulate the differ-
entiation of the cells by showing changes of a-smooth
muscle actin expression [4]. Cell differentiation seems
to regulate cell functions by changing the phenotypes
of the cells. Phenotypic changes occur in many types
of cells under various conditions [5, 6]. In vascular
smooth muscle cells, two phenotypes, namely synthetic
phenotype and contractile phenotype, are reported, and
the former changed from the latter loses contractile
function and induces cellular proliferation and protein
production such as extracellular matrices [7, 8].
Glomerular hyperfiltration prior to pathologic changes
such as glomerular basement membrane thickening and
mesangial expansion seems to be the first change in dia-
betic nephropathy [9, 10]. With respect to the regulation
of glomerular filtration, mesangial cells play an important
role by altering their cellular tone [11, 12]. Mesangial cells
during long-term high glucose conditions are reported to
lose their contractile response to contracting substances
such as angiotensin II and endothelin [13, 14]. Recent
studies have shown that high glucose concentrations can
induce phenotypic changes in mesangial cells [15, 16].
The phenotypic change in mesangial cells is considered
to occur in the early stage of diabetes in vivo [16].
Activation of PPARc by its ligands has been reported
to induce beneficial effects on PPARc expressing cells
by modulating their phenotype. PPARc ligands inhibit
macrophages in atherosclerosis and inflammatory func-
tions of activated monocytes in rheumatoid arthritis,
and induce apoptosis in neoplasms such as lung and
breast cancer [17–20]. Thiazolidinediones and 15deoxy-
12, 14 delta-prostaglandin J2 (15dPGJ2) are synthesized
PPARc ligands and natural PPARc ligand, respectively
[21]. Thiazolidinediones have been used as antidiabetic
drugs, and were reported to result in amelioration of dia-
betic nephropathy without affecting blood glucose levels
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and blood pressure in streptozotocin-induced diabetic
rats [22]. Recently, some of prostaglandin-synthesis in-
hibitors such as indomethacin and fenoprofen are re-
ported to act as PPARc ligands, while acetyl salicylic acid
does not [23].
Based on these observations, it is possible that PPARc1
in mesangial cells may be involved in the contractile dys-
function of the cells under high glucose environment by
changing the cellular phenotype through activation of
PPARc1. However, whether the expression of PPARc1
actually changes phenotype of the cells under high glu-
cose environment has not yet been determined.
The aim of the present study was done to determine
the expression PPARc1 in the presence of high glucose
concentrations, and to investigate whether activation of
PPARc1 by its ligands attenuates the reduced contractile
response of rat mesangial cells under the high glucose
condition.
METHODS
Cell preparation
Mesangial cells were isolated from kidneys of four-
week-old Sprague-Dawley rats by the differential sieving
procedure reported previously [24]. The cells were cul-
tured in plastic plates (Nunc Brand Products, Roskilde,
Denmark) in a 1:1 mixture of Dulbecco’s modified
Eagle’s medium (DMEM) and Ham’s F-12 (both from
Sigma, St. Louis, MO, USA) containing 10% fetal bovine
serum (FBS) (Gibco BRL, Grand Island, NY, USA),
10% Nu-serum (Collaborative Research, Bedford, MA,
USA), penicillin (100 U/mL), and streptomycin (100 lg/
mL) (Sigma). Rat mesangial cells at passages 3–5 from
five different preparations were used for the following
experiments.
Western blots of PPAR c1 and a-smooth muscle actin
Rat mesangial cells on 60 mm plastic plates (Nunc)
were cultured with DMEM-F12 containing 10% FBS
and 10% Nu-serum with either 5 or 20 mmol/L glu-
cose in the presence or absence of 10−6 mol/L piogli-
tazone, 10−5 mol/L 15dPGJ2, a natural PPARc ligands,
2× 10−5 mol/L indomethacin 10−4 mol/L acetyl salicylic
acid and 4 × 10−6 mol/L PD98059, which inhibits the
activation of mitogen-activated protein kinase (MAPK)
by mitogen-activated protein kinase kinase (MAPKK)
[25], for 5 days. The effect of protein kinase C (PKC)
activation with preincubation of 10−8 mol/L of 12-O-
tetradecarbonyl 13-acetate (TPA) for 20 minutes and the
effect of 10−11 mol/L tumor necrosis factor a (TNFa)
on PPAR c1 protein were also examined in the presence
and absence of PD98059 in DMEM-F12 with 5 mmol/L
glucose. The medium was changed every day. Western
blotting of PPARc1 and a-smooth muscle actin was per-
formed as described previously [4]. Briefly, mesangial
cells were harvested and lysed in a solution contain-
ing 20 mmol/L Tris/HCl, 150 mmol/L NaCl, 1 mmol/L
EDTA, 1 mmol/L DTT, 1 mmol/L phenylmethylsulfonyl
fluoride (PMSF), 1% Nonidet P-40 and 1% Triton X.
Protein extracts were obtained by centrifugation of the
lysate. The protein extract (25 lg) and positive controls
of PPARc1 protein from Jurkat whole cell lysate (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) were sepa-
rated on 10% non-gradient acryl amide gel using sodium
dodecyl acryl amide gel electrophoresis, then transferred
to nitrocellulose membranes. Rabbit immunoglobulin G
(IgG) antibodies against PPARc1 and a-smooth mus-
cle actin (both Santa Cruz Biotechnology) were reacted
(both at 1:1000 dilution), followed by peroxidase-linked
protein A (Amersham Life Science, Buckinghamshire,
UK). Immunoreactive bands were visualized by West-
ern blotting detection electrochemiluminescence (ECL)
reagents (Amersham) with the use of XOmatic AR film
(Eastman-Kodak, Rochester, NY, USA).
Cellular contraction experiment
Cellular contraction experiment was carried out by the
method previously described [26]. Briefly, rat mesangial
cells were incubated in DMEM-F12 with 10% FBS and
10% Nu-serum containing either 5 or 20 mmol/L glucose
in the presence and absence of appropriate concentra-
tions of pioglitazone, troglitazone, indomethacin, acetyl
salicylic acid, and 15dPGJ2 and PD98059 up to 5 days. The
medium was changed every day. Effects of angiotensin II
on the tonus of cells were examined by measuring the sur-
face area of the cells. The cellular surface area was mea-
sured using cells cultured on 6-well plates. The cells were
preincubated in DMEM-F12 with 5 mmol/L glucose con-
taining 10% FBS and 10% Nu-serum for 1 hour at 37◦C
in 95% air 5% CO2 gas mixture. Cells cultured on 6-well
plates were incubated in 20 mmol/L Tris/HEPES (pH 7.4)
buffer containing (in mmol/L) glucose 5, NaCl 145, KCl
5, MgSO4 2.5, and CaCl2 1 in the presence of 10−7 mol/L
angiotensin II after washing three times with the same
buffer. The cells were recorded by a light-microscope
equipped with a digital camera (Nikon, Tokyo, Japan)
for 30 minutes. Serial changes in the surface area were
calculated using NIH image software (written by Wayne
Rasband).
Reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was prepared from rat mesangial cells
cultured in the conditioned media using Isogen (Wako
Junyaku, Osaka, Japan). To amplify the PPARc1 and
GAPDH cDNA fragments, PCR primers for PPARc1
and GAPDH were synthesized as follows: forward primer
sequences (5′-CCTCTCTCTGATGGATGACC-3′) and
(5′-TGAACGGGAAGCT CACTGG-3′), and reverse
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Fig. 1. Effects of TNF-a (left) and TPA
(right) on peroxisome proliferator–activated
receptor c (PPARc)1 protein of rat mesangial
cells in 5 mmol/L glucose. The cells were
treated with TNF-a for 1 day and with TPA
for 2days, respectively. Relative density of
the PPARc1 protein compared to that in
5 mmol/L glucose was determined as de-
scribed in Methods. Upper panel: Western
blots of PPARc1 protein. Lower panel:
Relative density of PPARc1 protein. TNF-a,
tumor necrosis factor-a; TPA, 12-O-
tetradecarbonyl 13-acetate; Pio, pioglitazone.
Data are mean ± SEM. N = 4 in each
condition. ∗P < 0.01 vs. control.
primer sequences (5′-TTTCTACTCTTTTTGTCGAT-
3′) and (5′-TACAGCAACAGGGTGGTGGA-3′), re-
spectively. RT-PCR was performed using 1 lg of total
RNA from rat mesangial cells under different condi-
tions, an Oligo (dT) 15 primer (Promega, Madison, WI,
USA) and 0.5 lmol/L of each primer, using Ready-To-Go
RT-PCR Beads (Amersham Pharmacia Biotech, Inc.,
Piscataway, NJ, USA). Reverse-transcription to cDNA
was performed at 42◦C for 30 minutes. The temperature
program for the PCR amplification was 25 cycles of 30 sec-
onds at 94◦C, 30 seconds at 54◦C, and 30 seconds at 72◦C
for PPARc1, and 19 cycles of 30 seconds at 94◦C, 30 sec-
onds at 58◦C, and 30 seconds at 72◦C for GAPDH, using
a thermal cycler (model 9600, Perkin Elmer-Cetus, Foster
City, CA, USA). Each 8 lL of both PCR products
were mixed with a loading buffer and then were elec-
trophoresed in a 2% agarose gel. To confirm linearity of
RT-PCR products of PPARc1 and GAPDH, 0.5, 1, 2, 3 lg
of the stocked total RNA from mesangial cells cultured
in 5 mmol/L glucose were used.
Antisense DNA for PPARc1
Antisense DNA and sense DNA for PPARc1 were
synthesized as follows: antisense DNA sequences
(5′-TGTCAACCATGGTAA-3′) and sense DNA se-
quences (5′-TTACCATGGT TGACA-3′), respectively.
One lmol/L and 0.5 lmol/L of each antisense and sense
DNA in OPTI-MEM (Sigma) were prepared after treat-
ment with lipofectin for 15 minutes at room tempera-
ture. Rat mesangial cells on 60-mm plate and 6-well plate
were washed 3 times with OPTI-MEM, and then were
incubated in OPTI-MEM containing 0.5 and 1.0 lmol/L
of either antisense DNA or sense DNA for 6 hours, re-
spectively. The cells were washed 3 times with DMEM-
F12, and then were incubated in DMEM-F12 containing
5 mmol/L glucose and 20% FBS for 48 hours. The cells on
60-mm plates were harvested to examine a-smooth mus-
cle actin and PPARc1. The cells on 6-well plates were
used for the cellular contraction study.
Other determinations
To determine cell viability, confluent mesangial cells
on 96-well plate cultured in the media with different con-
centrations of pioglitazone for 5 days were used. The
viability was quantified by 3-(4,5-dimethylthiazol-2-yl)-
2,5-difenyltetrazolium bromide (MTT) assay purchased
from Promega. Densitometric analyses were conducted
using NIH image program.
Statistical analysis
Data were expressed as mean ± SEM. Differences be-
tween groups were examined for statistical significance
using analysis of variance (ANOVA) and paired and un-
paired Welch’s t test (two-tailed). A P value less than
0.01 denoted the presence of a statistically significant
difference.
RESULTS
Expression of PPARc 1 and of a-smooth muscle actin
The effect of TNFa and activation of PKC on PPARc1
protein is shown in Figure 1. TNFa suppressed the
PPARc1 protein after 24 hours. The PPARc1 protein
did not change 1day after activation of PKC (data not
shown); however, the protein decreased significantly af-
ter 2 days. The decreased PPARc1 protein by both TNFa
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Fig. 2. Serial changes in peroxisome proliferator–activated receptor c
(PPARc)1 protein of rat mesangial cells during incubation in 20 mmol/L
glucose for 5 days. Upper panel: Western blots of PPARc1 protein.
Lower panel: Relative density of PPARc1 protein. Data are mean ±
SEM. N = 16 in each condition. ∗P < 0.01 vs. 5 mmol/L glucose. Jurcut
cell: used as an internal standard for the PPARc1 protein.
and PKC activation was attenuated by the inhibition of
MAPK with PD98059. The decreased protein by PKC
activation was also attenuated by pioglitazone. The serial
changes in PPARc1 expressions of mesangial cells in 5
or 20 mmol/L glucose are shown in Figure 2. The expres-
sion of PPARc1 protein in cells treated with 20 mmol/L
glucose did not change until 3 days, and decreased sig-
nificantly after 5 days compared with that in 5 mmol/L
glucose. The effects of PPARc ligands and PD98059 on
PPARc1 protein of cultured cells for 5 days are shown
in Figure 3. Pioglitazone significantly increased PPARc1
protein compared to that in 5 mmol/L glucose. Piogli-
tazone, 15dPGJ2 and indomethacin prevented the sup-
pression of PPARc1 protein expression in 20 mmol/L
glucose. However, acetyl salicylic acid had no effect on
PPARc1 protein. MAPK inhibition by PD98059 also nor-
malized the expression of PPARc1 in 20 mmol/L glu-
cose. Effects of high glucose, TNFa, and PKC activation
on PPARc1 mRNA are shown Figure 4. These factors
significantly suppressed the mRNA, and the suppressed
mRNA expressions were attenuated by the addition
of PD98059. Pioglitazone increased PPARc1 mRNA in
5 mmol/L and 20 mmol/L glucose. Treatment of the cells
with 20 mmol/L glucose increased a-smooth muscle actin,
and this increased a-smooth muscle actin was normalized
by pioglitazone and indomethacin, but not by acetyl sal-
icylic acid (Fig. 5).
Effect of angiotensin II and high glucose
on cellular contraction
Representative photomicrographs of changes in sur-
face area of mesangial cells in response to angiotensin
II are shown in Figure 6. Angiotensin II decreased sur-
face area of mesangial cells in a dose-dependent man-
ner. Angiotensin II more than 10−8 mol/L significantly
reduced the area (Fig. 7A). The contractile response of
the cells in 20 mmol/L glucose to angiotensin II did not
differ from that in 5 mmol/L glucose until 3 days of in-
cubation, and then decreased significantly after 5 days
compared to those in 5 mmol/L glucose and in 20 mmol/L
glucose after 1 and 3 days incubation (Fig. 7B).
Effect of pioglitazone on angiotensin II-induced
contraction of rat mesangial cells in 5 and
20 mmol/L glucose
Figure 8A demonstrates the effect of various con-
centrations of pioglitazone on changes in surface area
of mesangial cells cultured in 5 or 20 mmol/L glucose
after 5 days. The contractile response of the cells to
angiotensin II under both glucose conditions was sig-
nificantly reduced in the presence of higher concentra-
tions of pioglitazone (10−4 and 10−5 mol/L). However,
10−6 and 10−7 mol/L of pioglitazone prevented the re-
duction of the contractile response in 20 mmol/L glucose.
Effect of pioglitazone on viability of rat mesangial cells
by MTT assay is shown in Figure 8B. The viability of
the cells in 5 mmol/L and 20 mmol/L glucose did not
change at the lower concentrations of pioglitazone up to
10−5 mol/L; however, 10−4 mol/L of pioglitazone signifi-
cantly decreased these viability of the cells, compared to
that in 5 mmol/L glucose without pioglitazone.
The effects of 15dPGJ2, indomethacin, PD98059,
and acetyl salicylic acid on the reduced
contractile response
15dPGJ2, indomethacin, and PD98059 normalized the
reduced contractile response in 20 mmol/L glucose to
the response in 5 mmol/L glucose, respectively. How-
ever, acetyl salicylic acid (10−4 mol/L) had no effect on
the reduced contractile response in 20 mmol/L glucose
(Fig. 9).
Effect of antisense DNA for PPARc1 on PPARc1
protein, a-smooth muscle actin, and contractile response
Both 0.5 and 1.0 lmol/L of antisense DNA sig-
nificantly suppressed PPARc1 protein and increased
a-smooth muscle actin, compared with those in DMEM-
F12 with 0.5 and 1.0 lmol/L of sense DNA (Fig. 10A
and B). Angiotensin II induced cellular contraction, and
a significant 35% decrease of surface area in 5 mmol/L
glucose alone was observed (Fig. 10C). Antisense DNA
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suppressed completely the contractile function of mesan-
gial cells. In the presence of sense DNA of 0.5 lmol/L and
1.0 lmol/L, angiotensin II significantly decreased the sur-
face area and the degrees of the decrease were 29% and
23%, respectively. The degree of the decrease of surface
area in 1.0 lmol/L sense DNA was significantly less com-
pared with that in 5 mmol/L glucose alone.
DISCUSSION
In the regulation of PPARc, tumor necrosis factor-a
(TNF-a) has been reported as an important factor to
suppress PPARc at both protein and mRNA level in
preadipocytes [27–30]. Low levels of PPARc1 mRNA
and protein have been reported in human macrophage
cultured in high glucose [31]. We demonstrated that high
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Fig. 5. Effects of peroxisome proliferator–
activated receptor c (PPARc) ligand, 10−6
mol/L pioglitazone (Pio), 2 × 10−5 mol/L in-
domethacin (Indo), 10−4 mol/L acetyl sali-
cylic acid (Asp) on a-smooth muscle actin of
rat mesangial cells after 5 days incubation in
20 mmol/L glucose. Upper panel: Western
blots of PPARc1 protein. Lower panel: Rela-
tive density of PPARc1 protein. N = 4 of each
condition. Data are mean ± SEM. ∗P < 0.01
vs. 5 mmol/L glucose. #P < 0.01 vs. 20 mmol/L
glucose.
glucose as well as TNF-a and PKC activation decreased
PPARcl at both the protein and mRNA levels in rat
mesangial cells. The suppression of PPARcl by these fac-
tors was normalized by the inhibition of MAPK. These re-
sults indicate MAPK activation down-regulates PPARcl
expression at the transcriptional level. The activation of
MAPK by TNFa and the suppression of PPARc action
by MAPK have been reported in macrophage [32, 33].
In high glucose environments, activation of the DAG-
PKC-ERK pathway has been reported to occur in rat
mesangial cells [34]. The mechanism of the suppression
of PPARcl under the high glucose condition seems to
be explained by the activation of DAG-PKC-ERK path-
way. The high glucose-induced PKC activation has been
reported to occur after 3 days in rat aortic smooth mus-
cle cells [35], which may explain the delay in suppressing
PPARcl protein under the high glucose condition.
We also demonstrated pioglitazone induced PPARcl at
both protein and mRNA levels. The induction of PPARcl
at mRNA and protein levels by troglitazone [36] and
the prevention of TNF-a–induced suppression in PPARcl
mRNA by troglitazone, pioglitazone, and 15d-PGJ2 [28,
37] have been also reported. We reported that troglita-
zone normalized the increased cellular redox potential
in rat mesangial cells in high glucose [38]. This effect of
troglitazone may normalize PKC activity, since the in-
creased cellular redox potential is reported to activate
PKC activity [39]. Pioglitazone has been reported to nor-
malize PKC activity in rat kidney [22]. The normaliza-
tion of PKC activity may normalize MAPK activity in
the DAG-PKC-ERK pathway. Indomethacin has been
reported to inhibit MAPK [40]; however, 15dPGJ2 and
thiazolidinediones have been reported to activate MAPK
recently [41, 42]. These reports indicate PPARc ligands
other than indomethacin directly promote PPARcl pro-
tein at the level of gene expression independent of MAPK
activity.
We examined a-smooth muscle actin as a marker of
phenotypes of mesangial cells. a-Smooth muscle actin is
not present in normal glomeruli and emerges in diseased
glomeruli such as diabetic nephropathy [43]. PPARc lig-
ands reversed the increased a-smooth muscle actin in
20 mmol/L glucose to the level in 5 mmol/L glucose. These
results suggest that PPARc in rat mesangial cells also reg-
ulates phenotypes of the cells as reported in adipocytes
[1, 29, 44], and the phenotypic change by the suppression
of PPARc1 under the high glucose condition is recovered
to the phenotype under the normal glucose condition by
PPARc ligands.
We also demonstrated the contraction of mesangial
cells by measuring changes in the surface area of the cells,
as reported previously [26]. The response of the cells to
angiotensin II was similar to those described in previ-
ous studies [45]. Interestingly, the contractile response
of the cells in 20 mmol/L glucose to angiotensin II de-
creased after 5 days incubation, which coincided with the
decrease in PPARcl protein. Moreover, the decreased
contractile response was attenuated by the normalization
of PPARcl protein with PPARc ligands. These results in-
dicate that the suppression of PPARc1 protein under the
high glucose condition induces the contractile dysfunc-
tion of mesangial cells by changing the phenotype of the
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Fig. 6. Representative morphologic changes of cultured rat mesangial
cells under various conditions after exposure to angiotensin II. Normal
glucose condition before (A) and after (B), high glucose condition be-
fore (C) and after (D), high glucose with 10−7mol/L pioglitazone before
(E) and after (F), and high glucose with 10−6 mol/L pioglitazone before
(G) and after (H) exposure to 10−7 mol/L angiotensin II.
cells, since phenotypic change is important for cells to
exhibit their functional properties, such as cellular con-
traction [7, 8, 46].
A recent study raised PKC-mediated cytoskeletal dys-
function as a mechanism for the decreased contractile
response in high glucose [47]. In this study, the decreased
contractile response in high glucose was also recovered by
the inhibition of MAPK with PD98059. Because MAPK
positioned the downstream of PKC, activation of MAPK
may be important for the decreased contractile response.
However, PPARc ligands have been reported to activate
MAPK as mentioned above [41, 42]. The suppression of
PPARc1 protein by the activation of MAPK rather than
the MAPK activation itself seems to be the cause of the
high glucose–induced contractile dysfunction of the cells.
Moreover, we demonstrated the suppression of
PPARc1 protein by the antisense DNA for PPARc1,
that we made, induced an increase of a-smooth muscle
actin and contractile dysfunction of mesangial cells in
5 mmol/L glucose. These results indicate that PPARc1
acts as a regulator of phenotype of mesangial cells and
that the decrease of PPARc1 action by the suppression
of its protein level induces de-differentiation of the cells,
of which contractile function is decreased simultaneously.
The concentration of pioglitazone, which attenuates
the high glucose–induced contractile dysfunction, is sim-
ilar to the serum concentrations in diabetic patients
treated with the same drug. Isshiki et al reported that
pioglitazone recovered the glomerular hyper filtration,
which is observed in the early stage of diabetic nephropa-
thy, without affecting the sustained high blood glucose
level in diabetic rats [22]. Normalization of PPARc1 pro-
tein by its ligands under the high glucose condition may
contribute the beneficial effect on glomerular filtration by
keeping the cellular phenotypes with normal contractile
function.
We demonstrated the higher concentrations of piogli-
tazone more than 10−5 mol/L decreased the contractility
of rat mesangial cells in this study. Similar to piogli-
tazone, the high concentration of troglitazone (2.5 ×
10−6 mol/L) decreased the contractility of the cells, and
lower concentration of the drug (2.5 × 10−7 mol/L) pre-
vented the reduced contractile response to in 20 mmol/L
glucose (data not shown). The cell viability did not change
at the concentration of pioglitazone up to 10−5 mol/L;
however, it significantly decreased at 10−4 mol/L of the
drug. Guan et al reported the similar effect of troglita-
zone on mesangial cells, and 2 × 10−5 mol/L of troglita-
zone decreased the cell viability, while 1 × 10−5 mol/L of
troglitazone did not [48]. Pioglitazone and troglitazone
have been reported to act as calcium channel blockers
in smooth muscle cells, and those concentration were re-
ported 3.0 × l0−6 mol/L and 4.5 × l0−5 mol/L, respec-
tively [49, 50]. Recently, pioglitazone and troglitazone
more than 10−5 mol/L were also reported to suppress
angiotensin II receptor at the transcriptional level [51].
These effects of pioglitazone on cell viability, calcium
channel, and angiotensin II receptor may explain the sup-
pression of the angiotensin II-induced cellular contrac-
tion at the higher concentration of the drug.
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Fig. 7. Changes in surface area of rat mesan-
gial cells in the presence of different concen-
trations of angiotensin II (A) and effect of
high glucose on 10−7 mol/L angiotensin II-
induced contraction of cells during incubation
in 20 mmol/L glucose for 5 days (B). Data
are mean ± SEM of 20 to 30 cells from 3
separate experiments. ‡P < 0.01 vs. 5 mmol/L
glucose (no agonist) ∗P < 0.01 vs. 5 mmol/L
glucose + angiotensin II. #P < 0.01 vs. 20
mmol/L glucose + angiotensin II.
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Fig. 8. Effect of pioglitazone on angiotensin II-induced contraction (A) and cell viability (B) of cells cultured in either 5 mmol/L or 20 mmol/L
glucose for 5 days. The changes in cell surface area in response to 10−7 mol/L angiotensin II were analyzed. Data are mean ± SEM of 20 to 30
cells from 3 separate experiments. ∗P < 0.01 vs. 5 mmol/L glucose + angiotensin II. #P < 0.01 vs. 20 mmol/L glucose + angiotensin II. (B) The cell
viability was analyzed using MTT assay as described in Methods. N = 6 of each condition. Data are mean ± SEM ∗P < 0.01 vs. 5 mmol/L glucose.
#P < 0.01 vs. 20 mmol/L glucose.
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Fig. 9. Effects of 10−5 mol/L 15 deoxy-12,
14 delta-prostaglandin J2 (15dPDJ2), 2 ×
10−5 mol/L indomethacin (indo), 10−4 mol/L
acetyl salicylic acid (Asp), and 4 × 10−6 mol/L
PD98059 on angiotensin II-induced contrac-
tion and change in surface area of rat mesan-
gial cells after 5 days incubation in 20 mmol/L
glucose. Data are mean ± SEM of 20 to 30
cells from 3 separate experiments. ∗P < 0.01
vs. 5 mmol/L glucose + angiotensin II. #P <
0.01 vs. 20 mmol/L glucose + angiotensin II
after 5 days incubation.
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Fig. 10. Effects of antisense DNA on
peroxisome proliferator–activated receptor
c(PPARc)1 protein, a-smooth muscle actin,
and contractile response to angiotensin II
of rat mesangial cells in 5 mmol/L glucose.
(A) The cells were treated with antisense and
sense DNA for 6 hours, and then incubated
in 5 mmol/L glucose for 2 days. Upper
panel: Western blots of PPARc1 protein.
Lower panel: Relative density of PPARc1
protein. Data are mean ± SEM. N = 4 in
each condition. ∗P < 0.05 vs. control. ∗∗P <
0.01 vs. control. (B) Upper panel: Western
blots of a-smooth muscle actin. Lower panel:
Relative density of a-smooth muscle actin.
Data are mean ± SEM. N = 4 in each
condition. ∗P < 0.05 vs. 0.5 lmol/L and 1.0
lmol/L sense DNA. (C) Data are mean ±
SEM of 40 to 50 cells. ∗P < 0.001 before
vs. after angiotensin II stimulation in each
condition. #P < 0.05 vs. 5 mmol/L glucose
alone. ##P < 0.01 vs. 5 mmol/L glucose alone.
†P < 0.01 vs. 0.5 lmol/L and 1.0 lmol/L sense
DNA.
The role of prostaglandin E2 on the reduced contractile
response of mesangial cells in high glucose has been re-
ported, since prostaglandin E2 decreases mesangial cell
tonicity, and an increased production of prostaglandin
E2 by mesangial cells in high glucose has also been re-
ported [52, 53]. The concentrations of indomethacin and
acetyl salicylic acid used in our study were sufficiently
high to suppress prostaglandin synthesis [54, 55]; how-
ever, only indomethacin as a PPARc ligand could attenu-
ate the reduced contractile response. These data suggest
that the reduced contractile response of cultured mesan-
gial cells in high glucose is independent of prostaglandin
E2.
CONCLUSION
We demonstrate that PPARc ligands attenuated the
decreased contractile response of mesangial cells under
the high glucose condition with the recovery of PPARcl
protein and phenotypes of the cells.
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